All In Biotech

Free tool

FAERS Monitor: Angiomax

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020873 or its brand name (Angiomax, Bivalirudin). Reports on generic versions are filed under their own applications.

Reports

992

Serious

906

91% of reports

Hospitalization

419

Death reported

155

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective200
  • off label use114
  • haemorrhage91
  • heparin-induced thrombocytopenia76
  • gastrointestinal haemorrhage45
  • thrombosis44
  • vascular stent thrombosis40
  • acute myocardial infarction36
  • hypotension33
  • thrombosis in device33
  • product use issue29
  • cardiac arrest25
  • haemorrhage intracranial25
  • thrombocytopenia25
  • deep vein thrombosis23

Reports by year received

View as table
YearReports
200421
200517
200617
20077
200813
200923
201024
201122
201229
201331
201446
201527
201632
201726
201829
201947
202065
202184
202293
202393
2024100
202591
202655

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,167 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
vascular stent thrombosisSignal40425.1312.816,180
heparin-induced thrombocytopeniaSignal76332.2267.124,386
thrombosis in deviceSignal33215.6153.96,769
haemorrhage intracranialSignal2535.524.1804
acute myocardial infarctionSignal3625.918.8838
haemorrhageSignal9118.515.21,493
thrombosisSignal4411.68.7417
gastrointestinal haemorrhageSignal4511.48.6419
deep vein thrombosisSignal237.55.0124
cardiac arrestSignal256.44.4109
thrombocytopeniaSignal254.73.270
hypotensionSignal333.52.557
product use issueSignal293.32.344
drug ineffectiveSignal2003.22.8324
off label useSignal1142.82.3132

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.